MADRIGAL PHARMACEUTICALS, INC.
Historical Data
View all| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 3, 2026 | $3.04 | $3.09 | $2.95 | $3.00 | 15.27M |
| Jul 2, 2026 | $2.95 | $3.19 | $2.87 | $3.04 | 17.38M |
| Jul 1, 2026 | $3.02 | $3.08 | $2.91 | $2.95 | 18.47M |
| Jun 30, 2026 | $2.97 | $3.06 | $2.93 | $3.02 | 9.68M |
| Jun 29, 2026 | $3.11 | $3.28 | $2.87 | $2.97 | 15.66M |
| Jun 28, 2026 | $3.20 | $3.26 | $2.97 | $3.11 | 16.31M |
| Jun 27, 2026 | $3.34 | $3.40 | $3.16 | $3.20 | 12.80M |
| Jun 26, 2026 | $3.27 | $3.49 | $3.10 | $3.34 | 8.55M |
Company Overview
MADRIGAL PHARMACEUTICALS, INC. operates in the communication services space within the Communication Services sector. The company generates the majority of its revenue from operating momentum, and has built a durable competitive position through scale, brand, and continued reinvestment. It serves customers globally and is headquartered in the United States. Reported figures on this page are generated for demonstration and are not investment advice.
Leadership
Board 9 · Independent 8 of 9| Date | Firm | Target | Rating |
|---|---|---|---|
| Jul 2 | Goldman Sachs | — | Hold |
| Jun 16 | Goldman Sachs | $3.42 | Overweight |
| Jun 11 | Wedbush | $3.58 | Buy |
| Jun 5 | Rosenblatt | $5.20 | Reduce |
| May 23 | Goldman Sachs | $3.18 | Reduce |
| May 22 | Goldman Sachs | — | Hold |
Politician Trades
View allWhat's Happening Right Now
- Sep 11, 2026 · Insider ↗ — An insider disclosed plans for another stock sale following recent multimillion-dollar trades.
- Sep 9, 2026 · Insider ↗ — An executive plans to sell $3.4M of stock for tax withholding purposes.
- Aug 12, 2026 · Board ↗ — Madrigal appointed a Johnson & Johnson executive to its board of directors.
- Aug 24, 2026 · Analyst ↗ — Analysts flagged 31% upside potential for MDGL shares with Strong Buy ratings.
- Sep 14, 2026 · Insider ↗ — A report examined whether insiders have recently sold Madrigal Pharmaceuticals shares.
Snapshot
Madrigal Pharmaceuticals reported FY2025 revenue of $958.40M, up 432.1% year-over-year, reflecting a steep commercial ramp. Despite this growth, the company posted a net loss of $288.28M and an operating loss of $300.10M, with R&D spending of $388.52M equal to 41% of revenue. Operating cash flow was negative $189.55M and free cash flow was negative $190.02M, against minimal capex of $467K. The company held $198.69M in cash and equivalents versus $339.88M in total debt at year-end.
Bottom Line
Madrigal's revenue base is scaling extremely fast, but heavy R&D investment continues to drive substantial net losses and negative free cash flow. With cash of $198.69M against $339.88M in debt and ongoing cash burn near $190M annually, the company's runway and future financing needs are key watchpoints even as top-line growth accelerates. Recent insider selling activity alongside bullish analyst upside calls presents a mixed signal for investors weighing growth against balance-sheet strain.